SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis Aug 3, 2017
New Study Further Demonstrates In Vitro Activity of SCYNEXIS’ Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains Jun 15, 2017
Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078 Jun 5, 2017
Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS’ Lead Agent to Combat Serious and Life-threatening Fungal Infections May 24, 2017
Potent in vitro Activity of SCYNEXIS’ SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention (CDC) May 11, 2017
SCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation Development Status May 8, 2017
Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS’ Lead Anti-infective Candidate SCY-078 Apr 25, 2017
SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID Apr 21, 2017
SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Apr 12, 2017
